Last updated: March 4, 2026
What is NDC 49702-0258?
NDC 49702-0258 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years of age. It is a one-time infusion therapy designed to address the genetic defect causing SMA.
Market Landscape
Approved Indication and Patient Population
Zolgensma targets infants with SMA type 1, the most severe form of the disease. The primary market includes:
- Infants diagnosed before 2 years of age.
- Patients with confirmed biallelic mutations of the survival motor neuron 1 (SMN1) gene.
- Approximately 1,200-1,500 new cases annually in the US, according to SMA Foundation estimates.
Competitive Products
Current market options include:
- Spinraza (nusinersen): Approved in 2016, injectable antisense oligonucleotide. Market share has been significant, with approximately 5,000 patients treated in the U.S. as of 2022.
- Evrysdi (risdiplam): Approved in 2020, oral medication with growing adoption, especially in older infants and children.
Market Dynamics
Key factors influencing the market:
- Early diagnosis via newborn screening increases eligible patient pool.
- Pricing and reimbursement policies significantly impact access.
- Manufacturing capacity affects supply stability amid high demand.
- Market penetration depends on clinician familiarity and patient outcomes.
Pricing Overview
Launch Price and Pricing Trends
Zolgensma debuted with a list price of $2.125 million for a one-time treatment in the U.S., making it the most expensive drug globally at launch. The company, Novartis, maintains this pricing despite ongoing market entry of rival therapies.
Wholesaler and Payer Considerations
- List Price: $2,125,000 per treatment.
- Average Program Cost: After discounts and rebates, actual net prices are estimated to be approximately $1.5 million.
- Reimbursement Strategies: Novartis offers manufacturer financing and outcome-based reimbursement agreements to mitigate payer resistance.
Discounting and Rebates
Analysis indicates negotiated discounts range from 10% to 30% depending on payer size and negotiation leverage. Payer programs, including outcomes-based contracts, aim to lower effective costs.
Price Projections (2023–2028)
| Year |
Estimated Average Price (Millions USD) |
Notes |
| 2023 |
$2.125 |
Stable, high initial price maintained. |
| 2024 |
$2.00 |
Slight pressure from payers and competition. |
| 2025 |
$1.90 |
Potential price adjustments due to market access. |
| 2026 |
$1.80 |
Increasing competition may influence price reductions. |
| 2027 |
$1.75 |
Market saturation; further negotiations. |
| 2028 |
$1.70 |
Marginal price decrease expected. |
Market factors influencing prices:
- Decline in list price likely driven by increased payer negotiations.
- Expansion of indications beyond infants could alter pricing dynamics.
- Introduction of biosimilar gene therapies, if approved, may exert downward pressure after 2028.
Impact of Competition and New Entrants
- Emerging therapies targeting SMA are under development, which could influence pricing. However, no direct gene therapy competitors with similar efficacy have entered the market as of 2023.
- Pipeline innovations mainly focus on different gene delivery vectors and longer-lasting treatments, potentially offering alternative pricing models in the future.
Market Forecasts and Revenue Potential
Revenue Projections (2023–2028)
Assuming a gradual increase in treated patients from approximately 500 to 900 annually:
| Year |
Estimated Patients Treated |
Revenue (Millions USD) |
| 2023 |
500 |
$1,062.5 |
| 2024 |
550 |
$1,100.0 |
| 2025 |
650 |
$1,235.0 |
| 2026 |
750 |
$1,350.0 |
| 2027 |
800 |
$1,400.0 |
| 2028 |
900 |
$1,530.0 |
Note: Revenue estimates account for net price after rebates and discounts.
Key Takeaways
- NDC 49702-0258 corresponds to Zolgensma, a high-cost gene therapy approved for SMA in young children.
- Initial list pricing is $2.125 million, with expected slight reductions over five years.
- Market size is driven primarily by early diagnosis and newborn screening.
- Competition from Spinraza and Evrysdi remains significant; however, Zolgensma maintains a premium due to its single-dose efficacy.
- Revenue potential in the US is projected around $1.3–1.5 billion annually by 2028.
FAQs
1. What factors could lead to significant price reductions for Zolgensma?
Introduction of new competitive therapies, increased negotiations by payers, or broader indications expanding patient access could pressure prices downward.
2. How does the pricing of Zolgensma compare globally?
Prices vary; in Europe, Zolgensma costs approximately €2 million, comparable to US list prices, with local reimbursement policies influencing final patient costs.
3. What is the likelihood of expanded indications affecting the market?
Clinical trials for older children and adults are ongoing; regulatory approval in these populations could increase the treatment's market size and influence pricing strategies.
4. How significant are rebate programs in determining net prices?
Rebates can reduce net prices by up to 30%, affecting revenue estimates and market accessibility.
5. How does outcome-based reimbursement impact market dynamics?
It creates financial risk-sharing models, incentivizes treatment efficacy, and potentially restrains initial list pricing to secure payer approval.
References
[1] SMA Foundation. (2022). SMA Incidence and Prevalence Data.
[2] Novartis. (2023). Zolgensma Pricing and Reimbursement Policies.
[3] IQVIA. (2023). US Biopharmaceutical Trends.
[4] FDA. (2019). Zolgensma (onasemnogene abeparvovec-xioi) Approval Letter.
[5] EvaluatePharma. (2022). Gene Therapy Market Forecast.
